<sup>18</sup>F-FDG PET/CT can better detect occult neck metastasis than CT/MR imaging, which may potentially impact the clinical management of OCC patients.
Comparison of <sup>18</sup>F-FDG PET/MRI, MRI, and <sup>18</sup>F-FDG PET/CT for the detection of synchronous cancers and distant metastases in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma.
Comparisons of CT features and <sup>18</sup>F-FDG metabolic indices between benign and malignant entities, as well as among primary and secondary malignancies and lymphoma, were performed.
The purpose of this study is to prospectively evaluate the performance of sodium <sup>18</sup>F]fluoride (Na[<sup>18</sup>F]F)/2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose ([<sup>18</sup>F]FDG) simultaneous time-of-flight enabled positron emission tomography (PET)/magnetic resonance imaging (MRI) for the detection of skeletal metastases in selected patients with advanced breast and prostate cancers.
We retrospectively reviewed F-FDG PET/CT studies of 117 patients (169 lesions), of which 65 had imaging of enostoses, and 52 had imaging showing the transition of lesions from untreated to treated osteoblastic metastases.
However, <sup>18</sup>F-FDG PET/CT is useful for the detection of interval metastases and might become useful in an active surveillance strategy with serial <sup>18</sup>F-FDG PET/CT scanning.
The aim of this study was to assess the diagnostic accuracy of preoperative <sup>18</sup>F-FDG PET or PET/CT in detecting pelvic lymph node (PLN) and para-aortic lymph node (PALN) metastasis in patients with endometrial cancer (EC) in systematic review and meta-analysis format.
The <sup>18</sup>F-FDG PET scan documented intensely hypermetabolic lymph nodes, which histologically corresponded to a metastasis from a small cell neuroendocrine carcinoma.
We investigated the prognostic value of F-FDG uptake in the supraclavicular lymph node (SCLN) on PET/CT in breast cancer patients with clinical ipsilateral SCLN metastasis (cN3c).
Sensitivity, specificity, positive and negative predictive values (PPV and NPV) were calculated for identification of high-grade histology (WHO III or IV, or metastatic disease) obtained post-FDG-PET/CT.
No differences between metachronous cancers and metastases were found in: patient's age (70.3±8.1years vs 69.5±9.7years), gender (males=63.1% vs 62.5%), interval between previous cancer diagnosis and nodules' detection (median time=4years vs 4.5years), location (right-lung=55% vs 54%; upper-lobes=64% vs 67%; central-site=31% vs 25%), size (median size=17mm vs 19.5mm), 18F-FDG standardized uptake value (median SUVmax=5.2 vs 5.9).
<b>Conclusions and significance:</b><sup>18</sup>F-FDG PET/CT or conventional imaging is comparable with regard to detecting distant metastases of recurrent HNSCC.
Those of <sup>18</sup>F-FDG PET/CT computer imaging combined with tumor marker examination for the recurrence and/or metastasis after NSCLC treatment were remarkably higher than those of either individual examination, and the accuracy difference of information feedback had significant statistical significance (P<0.05).
This study aims to investigate the effectiveness of <sup>18</sup>F-FDG PET and PET/CT in the diagnosis, staging, recurrence and metastasis formation observations of osteosarcoma through systematic review followed by meta-analysis.
Vice versa, highly F-FDG-avid lung lesions in patients with brain tumors should lead to distant metastases as differential diagnosis despite their rare occurrence.
Pathological N stage was concordant with both <sup>18</sup>F-FDG PET/MRI and <sup>18</sup>F-FDG PET/CT in 78% (n = 7) of cases.No subject had metastatic disease.
SUV<sub>max</sub> ratio between the cardiac focus and surrounding background cardiac uptake and status of distant metastases might help to differentiate malignant from benign nature of the focal cardiac uptake on FDG PET/CT.
A range of parameters including volumetric and heterogeneity measures were derived from FDG PET images of 52 patients with colorectal intrahepatic-only metastases (29 males and 23 females; mean age 62.9 years [SD 9.8; range 32-82]).